- The two companies entered co-marketing and distribution agreement to be implemented worldwide
- Pressure BioSciences’ high pressure generator technology can improve optical spectroscopy accuracy and data collection with potentially far-reaching impact on drug development
- The joint technology will be promoted to scientists all over the world and is expected to generate increased sales starting this year
A leading developer and provider of innovative high pressure-based solutions to the global life sciences industry, Pressure BioSciences, Inc. (OTCQB: PBIO) has entered a two-year agreement with ISS, Inc., a prominent designer and manufacturer of advanced scientific instruments with more than 30 years of experience in the field. Under the agreement, the two companies will join their marketing and distribution efforts worldwide, as well as their own technologies to create an advanced high pressure optical spectroscopy system that’s expected to generate significant data that could be critical to the discovery and development of new biopharmaceutical diagnostics and drugs, according to a Pressure BioSciences press release issued on February 14, 2018 (http://ibn.fm/hRbo0).
Optical spectroscopy is typically used by scientists all over the world as a powerful analytical method to generate and gather information about the composition of biological molecules. The collected data have multiple applications ranging from the design of new drugs to the development of preventive strategies against certain diseases. However, with high pressure optical spectroscopy, scientists have access to a more unique and effective way to study molecular interactions instantaneously and with a better control of reversibility and irreversibility, due to the easily adjustable duration and amount of applied pressure. This can greatly improve the speed and accuracy of data collection, helping scientists better understand how biological molecules function and interact, with a significant impact on the discovery and development of improved drugs and diagnostics.
ISS is confident that, by using Pressure BioSciences’ patented and game-changing pressure cycling technology (“PCT”) with its optical cell systems instead of current manual pressure generators, scientists will be able to “visualize biochemical reactions as they are happening in the pressure cell,” as noted by ISS President Dr. Ben Barbieri in a news release. “The Pressure BioSciences pressure generators will also facilitate automated and significantly faster data collection. Such systems could potentially have a significant and far-reaching impact on drug development and other important areas of biomedical research worldwide,” he added.
“This powerful combination of technologies will be promoted to scientists worldwide by both Pressure BioSciences and ISS, with the combined system expected to drive an increase in sales this year and beyond,” commented Dr. Nate Lawrence, PBIO VP of Marketing and Sales.
The ISS Agreement is the latest in a series of acquisitions and collaborations that Pressure BioSciences has entered into over the last few months, including, most notably, the acquisition of BaroFold, Inc.’s assets in December of last year and its entry into a strategic partnership with Phasex Corporation in October 2017. The BaroFold acquisition has significantly increased the company’s intellectual property estate by eight issued patents and several others that are pending, as noted by CEO Richard T. Schumacher on a ‘Stock Day’ podcast (http://ibn.fm/QuG2q).
With Phasex, the collaboration has allowed Pressure BioSciences to enter the fast-growing nanoemulsions market, where its proprietary PCT-based Ultra Shear Technology can be used with Phasex’s Supercritical Fluid processing to generate water-soluble, fully stable nanoemulsions. Ensuring stability of nanoemulsions has been a challenge until now, but this strategic collaboration has every chance to change that, leading to the further expansion of an already large market and an increase in the number of potential nanoemulsion applications in industries ranging from pharmaceuticals, nutraceuticals, cosmetics, paints and industrial lubricants to food and even medical cannabis (e.g., CBD).
Unlike most commercially-available emulsions, which tend to be unstable and sometimes inappropriate for human use due to a high amount of surfactants required, nanoemulsions have been shown to improve absorption, enhance stability, exhibit higher bioavailability, contain reduced amounts of surfactants and present multiple other advantages. Pressure BioSciences is confident that, with its patented Ultra Shear Technology, it will be able to develop commercial-scale nanoemulsions that require less emulsifying events, or even none at all.
For more information, visit the company’s website at www.PressureBioSciences.com
